Author: Ken Dropiewski

InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation

Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 SAN FRANCISCO, June 23, 2021 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing […]

CentraCare First in World to Use 4D Hologram Technology to Successfully Complete Structural Heart Procedure

EchoPixel’s pre-planning and intra-operative technologies reduced complex heart procedure time while improving quality of outcomes ST. CLOUD, Minn., June 23, 2021 (GLOBE NEWSWIRE) — CentraCare, one of the largest health systems in Minnesota, has successfully completed the first structural heart procedure in the world using 4D hologram technology, which was developed […]

BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

SAN CARLOS, Calif., June 23, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP™ […]

Andrew Hotchkiss joins Draupnir Bio as Chief Executive Officer

Copenhagen and Aarhus, Denmark, 23 June 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the appointment of Andrew Hotchkiss as Chief Executive Officer (CEO). Andrew brings more than 30 years of global experience in the pharmaceutical and biotechnology industries. He joins […]

Penumbra Announces FDA Clearance and Commercial Availability of RED 62 Reperfusion Catheter

Now available in the U.S., RED™ 62 is engineered with optimized trackability to help navigate the complex distal vessel anatomy in the brain and deliver powerful aspiration for the removal of blood clots First catheter of new RED series expands the company’s extensive portfolio of innovative stroke products ALAMEDA, Calif.–(BUSINESS WIRE)–Penumbra, […]

Fist Assist Devices, LLC Announces 510(k) Clearance for Focal Arm Massage and Increased Vein Circulation

LOS ALTOS HILLS, Calif.–(BUSINESS WIRE)–Fist Assist Devices, LLC, has received FDA 510(k) clearance for use of the Fist Assist FA-1 device in the United States as an arm massage and increased vein circulation device and has commenced marketing the Fist Assist FA-1 device for that indication for use. “We are […]

Angel Medical Systems Announces Brad Snow as Interim Chief Executive Officer

EATONTOWN, N.J., June 22, 2021 /PRNewswire/ — Angel Medical Systems, Inc., (dba AngelMed) announced today the departure of Gordie Nye as CEO of the company effective immediately. He will be succeeded by Brad Snow, an experienced leader in the medical device industry who has served in a variety of senior roles at several successful med-tech startups. […]

Ablacon Announces Martin Grasse as CEO and Clinical Study Progress

MENLO PARK, Calif., June 22, 2021 /PRNewswire/ — Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue with the company as Executive Chairman. “Marty has demonstrated exceptional leadership capabilities […]

Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have been in the news in recent days

– Genetics allows the study of risk related to hereditary cardiovascular disease, with special relevance in cardiomyopathies, arrhythmias and vascular involvement syndromes that may involve risk of sudden death. – The myCardio service designed by Veritas Intercontinental, a company focused on the study of genetic predisposition, includes all genes recommended […]